BRIEF-Incyte's Mid-stage Geometry Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results [Reuters]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Reuters
BRIEF-Incyte's Mid-stage Geometry Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results | Reuters 1 Min Read Oct 19 (Reuters) - Incyte Corp: * PHASE 2 GEOMETRY MONO-1 TRIAL OF INVESTIGATIONAL MEDICINE CAPMATINIB SHOWS POSITIVE RESULTS IN PATIENTS WITH MET-MUTATED ADVANCED NSCLC * ADVERSE EVENTS (AES) WERE CONSISTENT WITH PREVIOUSLY REPORTED DATA AND NO NEW SAFETY SIGNALS WERE OBSERVED IN STUDY * CLINICAL FINDINGS FROM ONGOING STUDY INDICATE SAFETY PROFILE WAS CONSISTENT WITH PREVIOUSLY REPORTED DATA RESULTS * NOVARTIS HAS EXCLUSIVE DEVELOPMENT & COMMERCIALIZATION WORLDWIDE RIGHTS TO CAPMATINIB Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved. BRIEF-Incyte's Mid-stage Geometry Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results Oct 19 (Reuters) - Incyte Corp: * PHASE 2 GEOMETRY MONO-1 TRIAL OF INVESTIG
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up [Yahoo! Finance]Yahoo! Finance
- Incyte Co. (NASDAQ: INCY) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $65.00 price target on the stock.MarketBeat
- Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Bank of America Co. from $69.00 to $67.00. They now have a "neutral" rating on the stock.MarketBeat
- Incyte (INCY) Posts Positive Results on Opzelura From HS Study [Yahoo! Finance]Yahoo! Finance
- Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 2/13/24 - Beat
INCY
Sec Filings
- 3/27/24 - Form 4
- 3/27/24 - Form 3
- 2/16/24 - Form 10-K/A
- INCY's page on the SEC website